Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial

Joseph Pidala, Mehdi Hamadani, Peter Dawson, Michael Martens, Amin M. Alousi, Madan Jagasia, Yvonne A. Efebera, Saurabh Chhabra, Iskra Pusic, Shernan G. Holtan, James L. M. Ferrara, John E. Levine, Marco Mielcarek, Claudio Anasetti, Joseph H. Antin, Javier Bolaños-meade, Alan Howard, Brent R. Logan, Eric S. Leifer, Theresa S. PritchardMary M. Horowitz, Margaret L. Macmillan

Research output: Contribution to journalArticle

3 Scopus citations
Original languageEnglish (US)
Pages (from-to)97-107
JournalBlood
Volume135
Issue number2
DOIs
StatePublished - Jan 9 2020
Externally publishedYes

PubMed: MeSH publication types

  • Journal Article

Cite this

Pidala, J., Hamadani, M., Dawson, P., Martens, M., Alousi, A. M., Jagasia, M., Efebera, Y. A., Chhabra, S., Pusic, I., Holtan, S. G., Ferrara, J. L. M., Levine, J. E., Mielcarek, M., Anasetti, C., Antin, J. H., Bolaños-meade, J., Howard, A., Logan, B. R., Leifer, E. S., ... Macmillan, M. L. (2020). Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. Blood, 135(2), 97-107. https://doi.org/10.1182/blood.2019003125